Status:
COMPLETED
Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients
Lead Sponsor:
University of Freiburg
Conditions:
Graft Versus Host Disease
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
In this study the investigators evaluate the outcomes of six steroid-refractory GVHD patients with gastrointestinal signs of GVHD that were treated with teduglutide.
Detailed Description
Preliminary studies have showed that Glucagon-like peptide 2 (GLP-2) has regenerative and protective effects on the gastrointestinal tract after bowel injury. It induces positive effects in the GI tra...
Eligibility Criteria
Inclusion
- Patients with signs of acute SR-GI-GVHD
- Age ≥ 18 years
- Peripheral blood and stool samples available before and during treatment
- Written informed consent
- Ability to understand the nature of the study and the study related procedures and to comply with them
Exclusion
- Age ≤ 18 years
- Lack of informed consent
Key Trial Info
Start Date :
December 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 6 2019
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04290429
Start Date
December 6 2017
End Date
December 6 2019
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center University of Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79106